1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015

TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 32 pages

TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the TaiGen Biotechnology Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TaiGen Biotechnology Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of TaiGen Biotechnology Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of TaiGen Biotechnology Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the TaiGen Biotechnology Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate TaiGen Biotechnology Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of TaiGen Biotechnology Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the TaiGen Biotechnology Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of TaiGen Biotechnology Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of TaiGen Biotechnology Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of TaiGen Biotechnology Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

TaiGen Biotechnology Co., Ltd. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
TaiGen Biotechnology Co., Ltd. Snapshot 5
TaiGen Biotechnology Co., Ltd. Overview 5
Key Information 5
Key Facts 5
TaiGen Biotechnology Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
TaiGen Biotechnology Co., Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
TaiGen Biotechnology Co., Ltd. - Pipeline Products Glance 10
TaiGen Biotechnology Co., Ltd. - Late Stage Pipeline Products 10
Pre-Registration Products/Combination Treatment Modalities 10
Phase III Products/Combination Treatment Modalities 11
TaiGen Biotechnology Co., Ltd. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
TaiGen Biotechnology Co., Ltd. - Early Stage Pipeline Products 14
Discovery Products/Combination Treatment Modalities 14
TaiGen Biotechnology Co., Ltd. - Drug Profiles 15
nemonoxacin 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
burixafor 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
furaprevir 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Small Molecules for Gram-Negative Bacterial Infections 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Small Molecules for Influenza 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
TaiGen Biotechnology Co., Ltd. - Pipeline Analysis 23
TaiGen Biotechnology Co., Ltd. - Pipeline Products by Target 23
TaiGen Biotechnology Co., Ltd. - Pipeline Products by Route of Administration 24
TaiGen Biotechnology Co., Ltd. - Pipeline Products by Molecule Type 25
TaiGen Biotechnology Co., Ltd. - Pipeline Products by Mechanism of Action 26
TaiGen Biotechnology Co., Ltd. - Recent Pipeline Updates 27
TaiGen Biotechnology Co., Ltd. - Dormant Projects 29
TaiGen Biotechnology Co., Ltd. - Locations And Subsidiaries 30
Head Office 30
Other Locations and Subsidiaries 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 31
Disclaimer 32

List of Tables
TaiGen Biotechnology Co., Ltd., Key Information 5
TaiGen Biotechnology Co., Ltd., Key Facts 5
TaiGen Biotechnology Co., Ltd. - Pipeline by Indication, 2015 7
TaiGen Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2015 8
TaiGen Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2015 9
TaiGen Biotechnology Co., Ltd. - Pre-Registration, 2015 10
TaiGen Biotechnology Co., Ltd. - Phase III, 2015 11
TaiGen Biotechnology Co., Ltd. - Phase II, 2015 12
TaiGen Biotechnology Co., Ltd. - Phase I, 2015 13
TaiGen Biotechnology Co., Ltd. - Discovery, 2015 14
TaiGen Biotechnology Co., Ltd. - Pipeline by Target, 2015 23
TaiGen Biotechnology Co., Ltd. - Pipeline by Route of Administration, 2015 24
TaiGen Biotechnology Co., Ltd. - Pipeline by Molecule Type, 2015 25
TaiGen Biotechnology Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 26
TaiGen Biotechnology Co., Ltd. - Recent Pipeline Updates, 2015 27
TaiGen Biotechnology Co., Ltd. - Dormant Developmental Projects,2015 29
TaiGen Biotechnology Co., Ltd., Subsidiaries 30

List of Figures
TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Indication, 2015 7
TaiGen Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2015 8
TaiGen Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2015 9
TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Target, 2015 23
TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015 24
TaiGen Biotechnology Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 25
TaiGen Biotechnology Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.